Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Takeda and Protagonist Therapeutics have shared positive top-line results from a phase 3 trial of rusfertide in the rare ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Key findings from the study include: The study’s primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy ... arm compared to 1.8 ...

BetterWay was recognized for its new, customer-friendly blood testing technology that collects pea-sized samples from the fingertip instead of tubes of blood from the arm. This press release ...